Bristol-Myers Squibb Co. and Celgene Corp. have entered a collaboration to evaluate the safety and efficacy of a combination regimen of BMS’ investigational PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene’s nab technology-based chemotherapy ABRAXANE, in a Phase I study. The study will examine the effect of the combination regimen in multiple tumor types, including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC). OPDIVO has been ...